Last reviewed · How we verify
Daunorubicine
Daunorubicine is a Small molecule drug developed by Gruppo Italiano Malattie EMatologiche dell'Adulto. It is currently in discontinued development for Acute lymphoid leukemia, Acute monocytic/monoblastic leukemia, Acute myeloid leukemia, disease. Also known as: DSP-DNR.
Daunorubicin is a chemotherapy medication used to treat various types of cancer, including leukemia and sarcoma, typically administered by injection into a vein. It works as a DNA topoisomerase II alpha inhibitor, a small molecule that targets and inhibits this enzyme.
At a glance
| Generic name | Daunorubicine |
|---|---|
| Also known as | DSP-DNR |
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Target | Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Approved indications
- Acute lymphoid leukemia
- Acute monocytic/monoblastic leukemia
- Acute myeloid leukemia, disease
- Acute promyelocytic leukemia, FAB M3
- Blast crisis of chronic myeloidleukemia
- Erythroleukemia, FAB M6
- Kaposi's sarcoma
Common side effects
Key clinical trials
- A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patie (Phase 3)
- Open-label, Dose-escalating Trial to Evaluate the Tolerability, Toxicity, Safety, Pharmacokinetics, Pharmacodynamics and Activity of Volasertib Added to the Standard Intensive Salvage Chemotherapy Reg (Phase 1)
- National Phase IIIb Prospective Two-Cohort Non-Randomized, Multi-centre, Open Label Study to Assess the Safety of Subcutaneous Trastuzumab and Molecular Biomarkers in Patients With Early and Locally A (Phase 3)
- A Randomised Phase II Feasibility Study Investigating the Biological Effects of the Addition of Zoledronic Acid to Neoadjuvant Combination Chemotherapy on Invasive Breast Cancer (Phase 2)
- iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes (NA)
- A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY AND RADIATION THERAPY IN THE MANAGEMENT OF HIGH-RISK, HIGH-GRADE, SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND BODY WALL (Phase 2)
- A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes (Phase 2)
- A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-supported Sequential Administration of FE75C Followed by Docetaxel Versus Docetaxel/Cyclophosphamide Doublet as Adjuvant Chemotherapy in (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daunorubicine CI brief — competitive landscape report
- Daunorubicine updates RSS · CI watch RSS
- Gruppo Italiano Malattie EMatologiche dell'Adulto portfolio CI
Frequently asked questions about Daunorubicine
What is Daunorubicine?
What is Daunorubicine used for?
Who makes Daunorubicine?
Is Daunorubicine also known as anything else?
What development phase is Daunorubicine in?
What does Daunorubicine target?
Related
- Target: All drugs targeting Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2
- Manufacturer: Gruppo Italiano Malattie EMatologiche dell'Adulto — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute lymphoid leukemia
- Indication: Drugs for Acute monocytic/monoblastic leukemia
- Indication: Drugs for Acute myeloid leukemia, disease
- Also known as: DSP-DNR
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing